Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2007
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study
Michael Herold, Antje Haas, Stefanie Srock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2018
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
Wolfgang Hiddemann, Anna Maria Barbui, Miguel A Canales, et al.
Blood Advances
|
March 22, 2021
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
Carla Casulo, Jesse G Dixon, Fang-Shu Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2023
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
Christiane Pott, Vindi Jurinovic, Judith Trotman, et al.
Hemasphere
|
July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
William Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Hemasphere
|
June 28, 2021
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
Carsten Hirt, Eva Hoster, Michael Unterhalt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Qian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.
Analytical Chemistry
|
April 24, 2026
Best Practices in GC-MS and GC × GC-MS-Based Metabolomics and Volatile Analyses: An International Survey
Ryland T Giebelhaus, Michael Herold, James J Harynuk, et al.
Blood
|
March 5, 2016
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
Sascha Dietrich, Andreas Pircher, Volker Endris, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2007
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study
Michael Herold, Antje Haas, Stefanie Srock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2018
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
Wolfgang Hiddemann, Anna Maria Barbui, Miguel A Canales, et al.
Blood Advances
|
March 22, 2021
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
Carla Casulo, Jesse G Dixon, Fang-Shu Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2023
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
Christiane Pott, Vindi Jurinovic, Judith Trotman, et al.
Hemasphere
|
July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
William Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Hemasphere
|
June 28, 2021
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
Carsten Hirt, Eva Hoster, Michael Unterhalt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Qian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.
Analytical Chemistry
|
April 24, 2026
Best Practices in GC-MS and GC × GC-MS-Based Metabolomics and Volatile Analyses: An International Survey
Ryland T Giebelhaus, Michael Herold, James J Harynuk, et al.
Blood
|
March 5, 2016
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
Sascha Dietrich, Andreas Pircher, Volker Endris, et al.
Page
of 4